Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Acquired by Two Seas Capital LP

Two Seas Capital LP increased its stake in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 4.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,740,956 shares of the biopharmaceutical company's stock after buying an additional 353,568 shares during the period. Arbutus Biopharma accounts for about 2.5% of Two Seas Capital LP's portfolio, making the stock its 11th largest position. Two Seas Capital LP owned 4.61% of Arbutus Biopharma worth $28,583,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in ABUS. Rangeley Capital LLC purchased a new stake in shares of Arbutus Biopharma in the fourth quarter valued at approximately $4,771,000. JPMorgan Chase & Co. boosted its holdings in shares of Arbutus Biopharma by 900.4% in the fourth quarter. JPMorgan Chase & Co. now owns 896,258 shares of the biopharmaceutical company's stock valued at $2,931,000 after purchasing an additional 806,672 shares during the period. BlackBarn Capital Partners LP boosted its holdings in shares of Arbutus Biopharma by 13.1% in the fourth quarter. BlackBarn Capital Partners LP now owns 2,341,871 shares of the biopharmaceutical company's stock valued at $7,658,000 after purchasing an additional 270,971 shares during the period. Barclays PLC boosted its holdings in shares of Arbutus Biopharma by 466.3% in the third quarter. Barclays PLC now owns 272,029 shares of the biopharmaceutical company's stock valued at $1,047,000 after purchasing an additional 223,995 shares during the period. Finally, Quinn Opportunity Partners LLC boosted its holdings in shares of Arbutus Biopharma by 72.2% in the fourth quarter. Quinn Opportunity Partners LLC now owns 404,879 shares of the biopharmaceutical company's stock valued at $1,324,000 after purchasing an additional 169,747 shares during the period. 43.79% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $5.00 price target on shares of Arbutus Biopharma in a report on Tuesday, January 21st. Chardan Capital restated a "buy" rating and set a $5.00 target price on shares of Arbutus Biopharma in a report on Friday, March 28th. Finally, StockNews.com upgraded Arbutus Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, March 29th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $5.50.

Arbutus Biopharma Stock Performance

Arbutus Biopharma stock traded up $0.05 during mid-day trading on Monday, reaching $3.34. 625,357 shares of the company were exchanged, compared to its average volume of 989,934. The business has a fifty day moving average of $3.28 and a 200 day moving average of $3.44. The firm has a market cap of $639.54 million, a P/E ratio of -7.77 and a beta of 1.45. Arbutus Biopharma Co. has a 12-month low of $2.63 and a 12-month high of $4.73.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The business had revenue of $1.57 million for the quarter, compared to the consensus estimate of $2.20 million. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. Sell-side analysts predict that Arbutus Biopharma Co. will post -0.39 EPS for the current year.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.